Arecor Ltd, the UK-based leading formulation technology company, focused on developing superior biopharmaceuticals via the innovative reformulation of proteins and peptides, is pleased to announce its participation at the Bioprocessing Summit, 13^th-17^th August 2018, at the Sheraton Boston Hotel, Boston, Massachusetts, USA. 

The Bioprocessing Summit convenes more than 1,000 international bioprocess professionals to share practical solutions for today's bioprocessing challenges. Now in its tenth year, the event has grown to include 17 distinct conferences with weeklong programming on upstream and downstream processing, analytical development and quality, formulation and stability, cell and gene therapy production, and manufacturing. Along with the impressive array of conferences, the Summit also includes short courses and training seminars that provide in-depth coverage of critical bioprocess topics. For more information about the summit, please visit http://www.bioprocessingsummit.com/

Arecor’s Chief Scientific Officer, Dr Jan Jezek, will be running one of the Short Courses and will give two presentations with a number of cases studies demonstrating the power of Arecor’s proprietary technology to develop differentiated biopharmaceutical products.

Thursday 16th, 6pm-9pm

Short course: Development of Innovative and Competitive Biologic Formulations in a Complex Patent Landscape

Monday 13th, 3:15pm

Formulation Challenges in the Increasingly Complex Patent Landscape

Thursday 16th, 9:00am

Successful High-Concentration Products – Creative Formulation and Device Choice

Dr Jan Jezek, Chief Scientific Officer at Arecor, commented: “I am delighted to have the opportunity to present at the Bioprocessing Summit this year. Having attended this conference several times in the past, I know that it is an excellent forum to learn about the latest advances in biopharmaceutical development and have a number of very interesting discussions with a wide range of interesting people. Arecor keeps making great strides in developing highly differentiated biopharmaceutical products through application or our proprietary formulation technology. In order to succeed it is critical for us to keep up-to-date with the latest developments in the industry as well as receiving a constructive feedback on our technology and product strategy. The Bioprocessing Summit is an excellent event to achieve that.”

To view the full release click here.